Volm M, Efferth T, Mattern J
German Cancer Research Center, Heidelberg.
Anticancer Res. 1992 Jan-Feb;12(1):11-20.
The expression of the protooncogene encoded proteins (c-erbB1, c-erb B2, c-myc, c-fos) and the suppressor gene product p53 was analyzed in 81 human squamous cell carcinomas of the lung and correlated with clinical parameters of the patients (patient survival, presence of metastases and tumor stage) and with biological characteristics of the tumors (tumor growth in nude mice, DNA-ploidy, proliferative activity, drug-resistance and P-glycoprotein or gluathione S-transferase expression). By means of immunohistochemistry, expression of c-erbB1 oncoprotein (EGF-receptor) was detected in 79% of the tumors, c-erbB2 (c-neu) proteins in 35%, c-myc proteins in 48%, c-fos proteins in 41%, and p53 in 43% of the tumors. Patients with c-erbB1 positive tumors had a poor prognosis (p = 0.021). In addition, these tumors were more frequently drug resistant (p = 0.0067). A significant correlation between the growth of the squamous lung carcinomas in nude mice and c-fos oncoprotein expression was demonstrated (p = 0.017). Therefore, EGF-receptor and c-fos products may serve as prognostic factors for the aggressiveness of squamous cell carcinomas of the lung and for the response of these tumors to chemotherapy. No significant correlation was found between the expression of the c-erbB1 or c-fos gene products and stage, metastasis and DNA-ploidy. In contrast to these results, no relationship was found between c-neu or c-myc gene products expression and any of the clinical or biological parameters examined. Aneuploid squamous cell carcinomas of the lung expressed p53 more frequently than diploid tumors (p = 0.027). However, there was no significant difference between p53 expression and stage, survival of patients, metastasis, growth of the tumors in nude mice, proliferative activity and drug-resistance of the tumors.
对81例人肺鳞状细胞癌中原癌基因编码蛋白（c-erbB1、c-erb B2、c-myc、c-fos）和抑癌基因产物p53的表达进行了分析，并与患者的临床参数（患者生存率、转移情况和肿瘤分期）以及肿瘤的生物学特性（裸鼠肿瘤生长、DNA倍体、增殖活性、耐药性以及P-糖蛋白或谷胱甘肽S-转移酶表达）进行了关联分析。通过免疫组织化学方法，在79%的肿瘤中检测到c-erbB1癌蛋白（表皮生长因子受体）的表达，35%的肿瘤中检测到c-erbB2（c-neu）蛋白的表达，48%的肿瘤中检测到c-myc蛋白的表达，41%的肿瘤中检测到c-fos蛋白的表达，43%的肿瘤中检测到p53的表达。c-erbB1阳性肿瘤患者的预后较差（p = 0.021）。此外，这些肿瘤更常具有耐药性（p = 0.0067）。肺鳞状细胞癌在裸鼠中的生长与c-fos癌蛋白表达之间存在显著相关性（p = 0.017）。因此，表皮生长因子受体和c-fos产物可能作为肺鳞状细胞癌侵袭性及这些肿瘤对化疗反应的预后因素。未发现c-erbB1或c-fos基因产物的表达与分期、转移及DNA倍体之间存在显著相关性。与这些结果相反，未发现c-neu或c-myc基因产物的表达与所检测的任何临床或生物学参数之间存在关联。肺非整倍体鳞状细胞癌比二倍体肿瘤更频繁地表达p53（p = 0.027）。然而，p53表达与分期、患者生存率、转移、肿瘤在裸鼠中的生长、增殖活性及肿瘤耐药性之间无显著差异。
